VitusCare is a dialysis care provider. VitusCare has raised $3 million in a Series B funding round. The investment round saw active participation from the Singapore-based healthcare growth equity firm, Liberty Ridge Capital, with participation from existing investors 1Crowd and 3i Partners, and several angel investors including Equentis, HDFC Bank, and NAFA Capital Advisors. The company raised approximately $2.7M in a Series A round led by Tomorrow Capital in April 2024 and ₹10.83 crore in a seed round in 2019.
Financial performance and operational scale
The fresh funding will be used to continue growing its dialysis centre network, developing new technology, building its workforce and expanding abroad, according to a press release from VitusCare.
The milestone comes at a time when VitusCare has seen its revenue grow by nearly 3X since the last funding round in 2024. The fresh funding follows continued support from institutional and individual investors as the company expands its healthcare presence in multiple regions.
VitusCare was established in 2017 by Prabhat Shrivastava and is based on a capital-efficient shop-in-shop model as opposed to standalone facilities. In this model, the company works with already established hospitals, providing specialized dialysis services through equipment, trained healthcare providers, technology, and operational support, while leveraging existing hospital infrastructure.
The setup allows providers to grow and scale with lower capital expenditures, especially in Tier II and Tier III cities. VitusCare has grown its network of dialysis centres from 22 to over 60, operating in 9 states and more than 50 cities.
The company has managed over 35,000 patients and performed more than 8 lakh dialysis sessions. During the same time, its number of employees has increased from 110 to 300, reflecting expanding centre operations and broader extension of patient care needs.
VitusCare’s corporate EBITDA performance in FY26 was positive and was helped by higher breakeven at the newly built centres and same-centre growth of more than 30%. Going forward, the company’s ambition is to grow the network to over 100 centres by the end of FY27 and explore select Asian markets.
VitusCare is also working on artificial intelligence-integrated business modules to enhance healthcare outcomes and to create a Technician Academy to train dialysis personnel.
These initiatives closely reflect the firm’s stated use of funds to bolster technology capabilities and workforce development to scale operations in existing and new geographies. The next growth phase has key operational areas, including building internal training capacity through AI-native modules and the creation of a dedicated academy.
Competitive landscape
VitusCare has been set up in a competitive dialysis and kidney care sector which features other participants like NephroPlus, Apex Kidney Care, DCDC Kidney Care, 7Med and Rahi Care. Activity has also expanded into a larger geographical area, with significant capital gains at peer firms.
Capital efficiency, clinical staffing, and centre-level execution are major drivers as multiple operators expand specialised renal care services and compete for a slice of the market and hospital partnerships for patient volume.
Conclusion
The $3-million series B funding marks another investment milestone for VitusCare, a Gurugram-based dialysis care provider, which has been growing its revenue since 2024 and is showing positive corporate EBITDA in FY26. The company is backed by investors Liberty Ridge Capital, NAFA Capital Advisors, 1Crowd, 3i Partners, Equentis, and angel investors, to expand its capital-light shop-in-shop concept from over 60 centres to over 100 centres by the end of FY27. VitusCare has taken the next step given its plans for technology development, AI infrastructure, a Technician Academy, and a first-of-its-kind expansion into some Asian markets amidst active competition across the dialysis care landscape.
Read the full article here


